Pharmaceutical CDMO Market (By Product: API; By Drug Product: Oral Solid Dose, Semi-solid dose, Liquid Dose, Others; By Dosage Form: Solid, Semi-Solid, Gas Dose Formulation, Liquid Dose Formulation; By Indication: Cancer, Cardiovascular Disease, Diabetes, Pain, Respiratory disease, Other Disease; By End-User) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032


The global pharmaceutical CDMO market size was estimated at USD 94.17 billion in 2022 and it is projected to hit around USD 172.02 billion by 2032, growing at a CAGR of 6.21% during the forecast period 2023 to 2032.

Pharmaceutical CDMO Market Size 2023 To 2032

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Key Takeaways:

  • By Product, the API segment dominated the market with the largest market share in 2022. However, the drug product is expected to increase in the expected time period.
  • By Workflow, the commercial segments had the largest market share in the Pharmaceutical CDMO market in the anticipated timeframe. Additionally, the clinical segment is the fast-growing segment in the Pharmaceutical CDMO market in the predicted period.
  • By Application, the oncology segment accounted for the largest market in the anticipated time period with the largest market revenue. Cardiovascular diseases and diabetes is one the largest emerging segment in the forecast period.
  • By Region, Asia-pacific had the largest market in terms of market size in 2022. Regions like North America and Europe are emerging as growing regions in the Pharmaceutical CDMO market.

Pharmaceutical CDMO Market Overview

Many pharmaceuticals industry are struggling with the manufacturing of drug substances, and the handling of pharmaceutical applications like manufacturing of the drug, pharmaceutical industry, keeping expenses in mind and also reducing the cost of the drug, higher need for equipment with affordable cost, to keep an eye on all these pharmaceutical industrial factors the Contract Development and manufacturing organization (CDMO) comes in partnership with the pharmaceutical industries to form innovative formulas and products into the market without investing additional expenses or infrastructure to support.

The Pharmaceutical CDMO handles the outsourcing of drug substances and works with innovation and development program that occurs before manufacturing one. The Pharmaceutical CDMO is one of the most important factors for the positive substantial growth of the healthcare industry.

Market Growth

The contract development and manufacturing organization works with the production, innovation, analysis, and development of the pharmaceutical industries. Hence the pharmaceutical industry doesn't have to build any other member of the team for innovation and development facilities. The Pharmaceutical CDMO provides the services such as packaging and shipment, blending, coating, analytic services, etc. CDMO works with formulation and preformation development services and commercial and clinical services. The Pharmaceutical CDMO is very essential part of the healthcare industry in terms of current market conditions.

The Increase in the population all over the world would create major healthcare opportunities in the forecast period. The ever-rising need for the pharmaceutical industry and manufacturing and development the contract development and manufacturing organization is important to manage all the innovation and development programs under one roof. The CDMO provide the pharmaceutical industries with the outsourcing of drug in lessen time and in a cost-effective manner. The increase in the investment in research and development programs from the pharmaceutical industry will result in an increase in the development of the pharmaceutical CDMO industry.

The rising investment into the research and development program on CDMO pharmaceuticals across the world will result in an increase in the market. The growing need for technological advancement in the pharmaceutical industries and drug development and production in the healthcare industry will be expected to rise up the market for Pharmaceutical CDMO.

Pharmaceutical CDMO Market Scope

Report Coverage Details
Market Size in 2023 USD 100.02 Billion
Market Size by 2032 USD 172.02 Billion
Growth Rate from 2023 to 2032 CAGR of 6.21%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Product, By Drug Product, By Dosage Form, By Indication, and By End-User
Regions Covered North America, Europe, Asia-Pacific, Latin America and Middle East & Africa


Pharmaceutical CDMO Market Dynamics:

Drivers:

An increase in chronic disease treatment will likely to drives the market

The contract development and manufacturing organization is work with the development and production of the drug as well as the technological advancements in the pharmaceutical industry. The increasing prevalence of chronic diseases in the population will end up on the increase in the need for advanced and effective treatment for the quick and better cure of people. The rise in chronic diseases like cancer is driving the market. Cancer causes the largest amount of death over the decades. The rising need for the advancement of treatment and increasing demand for the treatment of cancer will drive the pharmaceutical and contract development and manufacturing organization market.

Furthermore, the growth in generic medicines and personalized medicine will also have a positive impact on the contract development and manufacturing organization market. Technological advancement of the healthcare industry, finished drug formulation. Increasing collaboration among pharmaceutical industries, rising research and development investments, increase in old aged population will result in higher market growth of the pharmaceuticals CDMO market.

Restraints:

Lower profit share for the pharmaceutical industry

The Involvement of the outsourcing firm in the production of pharmaceutical drugs and technological advancement for the healthcare industry would result in a lower profit share for the pharmaceutical industry. The factors like raw materials, the number of purchased orders, labor force will affect the investment done by the pharmaceuticals industry. In outsourcing production like Pharmaceutical CDMO, there is an issue in visibility into the manufacturing process as compared to the in-house manufacturing process. If there are any manufacturing and production defects done by Pharmaceutical CDMO, the pharmaceuticals industry would be responsible for the problem and there is reputational damage to the firm.

Opportunities:

Technological advancement in the CDMO

Pharmaceutical contract development and manufacturing organization (CDMO) carries innovative operational technologies. The increase in the demand for precision medicine and generics medicines will result in future growth opportunities in the contract development and manufacturing organization market. Technological advancements such as deployment of artificial intelligence, block chain, cloud computing and machine learning are expected to offer lucrative opportunities for the market’s growth during the forecast period.

The pharmaceutical CDMO is setting goals towards technology leadership and is projected to increase in the upcoming decades. The rising merger and acquisition in the contract development and manufacturing organization will expand the market growth.

Product Insights:

The API segment held the largest market revenue in the contract development and manufacturing organization market in 2022, the segment will continue to grow at a significant rate during the forecast period. The API (Active Pharmaceutical Ingredients) is the initial form of the final drug product. The contract development and manufacturing organization made the major investment in the APIs market as there is an increase in the demand for the segment. The API is useful for the diagnosis, cure, and treatment or prevention of diseases that affect the human body. The API includes the type of drug like innovative and generic drugs.

The drug segment will increase significantly in the contract development and manufacturing organization market in the forecast period. The drug segment includes oral solid dose, semi-solid dose, liquid dose, and others. The drug type is useful for the treatment of several diseases. The growing number of chronic diseases within the population results in the growth in the drug segment.

Dosage Form Insights:

Solid Dose had the largest market size in the contract development and manufacturing organization in 2022. The demand for the solid dose segment is attributed to the longer shelf-life and the instant effect of the medicine will expand the demand for the solid dose segment in the predicted timeframe. The outsourcing of solid doses for the Pharmaceutical CDMO will be expanding due to the higher demand of the segment.

Gases Dose is significantly increasing in the contract development and manufacturing organization in the forecast period. Gases do include inhalers and aerosol. The changing environmental conditions and increase in diseases related to the lungs and intestines are expanding the market demand for the gases dose segment.

Indication Insights:

The pain indication segment is rising significantly in the contract development and manufacturing organization in the analyzed period. The rising demand for pain indication treatment demand increases the treatment of chronic pain in the human body. The demand for the pain indication segment is expanding due to the rise in the geriatric population across the globe. Outsourcing pain relief medication production will help the pharmaceutical industry to lower the cost.

End-User Insights:

The big pharmaceutical industry holds the largest market segment in the contract development and manufacturing organization market in 2022. The big pharmaceutical industries had the bulk of investment in the Pharmaceutical CDMO market and can invest in drug development and production. Outsourcing and manufacturing of drugs to CDMO will reduce the cost of the drug and help the big pharmaceutical industry to compete in the market.

The small and medium-scale pharmaceutical industry will show steady growth in the contract development and manufacturing organization in the analyzed period. Lack of capital and potential to invest in advanced facilities hamper the growth of small-scale pharmaceutical companies.

Regional Insights:

Asia-Pacific holds the largest market share of the contract development of manufacturing organizations in the anticipated timeframe, the region is expected to grow at a significant rate during the forecast period. The growth of pharmaceutical CDMO market in the region is attributed to the increasing population in the countries such as India and China. The rising population in this region results in an increased demand for advanced and reliable medical facilities. The development of a contract development and manufacturing organization market in the Asia-Pacific region is due to the lower cost of the manufacturing industries, lower labor cost, and beneficial government regulations. The increasing demand for generic and personalized medicines in these regions will support in continuing the dominance of the Asia-Pacific region in the Pharmaceutical CDMO market.

Pharmaceutical CDMO Market Share, By Region, 2022 (%)

North America is another largest marketplace for pharmaceutical CDMO services. The region is expected the boost due to the expansion of manufacturing units of pharmaceutical industries. The rise in the geriatric population in this region would result in a higher demand for such services form the healthcare industry. Growing technological innovation in the pharmaceutical industry will propel contract development and manufacturing organization market growth. Moreover, the well-established healthcare infrastructure along with favorable government policies in improving healthcare services supplements the growth of the market in North America.

Europe is expected to witness a noticeable growth in the pharmaceutical CDMO market during the forecast period. Countries including France, United Kingdom and Germany are expected to be the largest contributors for the growth of the market in Europe. The region is expected to grow with the rising investment in the pharmaceutical sector for a better healthcare system.

Recent Developments:

  • In March 2022, Acanthus Research Inc. works with providing high-end reference standards and organic synthesis service launches the Acanthus Pharma Service a CMDO service for the pharmaceutical and biotech services.
  • In Oct 2022, Medipost announced the launch of new CDMO business for cell and gene therapy products in Korean market. With the launch of such services, Medipost is planning for the one-stop solution for the development of overall pharmaceuticals and biopharmaceuticals products.
  • In April 2023, The Bridgewest Group, the global private investment company that works with life science software and contract development and manufacturing organization launched a new Sterile injectables CDMO NovaCina. NovaCina develops the product into a full-scale commercial product.
  • In May 2022, Hanmi Pharmaceutical Group’s subsidiary Hanmi Fine Chemical announced that it is expanding their services from API to the Contract Development and manufacturing organization services. Hanmi Fine Chemical will invest 10 Billion KRW to develop CDMO services.
  • In Jan 2023, Vector Biomed raised funding of $15 mn to enter into a CDMO services as a startup. With the raised funding, the company aims to fill the gap of manufacturers of gene and cell therapies.

 Pharmaceutical CDMO Market Companies

  • Bushu Pharmaceuticals Ltd.
  • Nipro Corporation
  • Thermo Fisher Scientific Inc.
  • Samsung Biologics
  • Laboratory Corporation of America Holdings
  • Siegfried Holding Ag
  • Catalent, Inc
  • Lonza Group AG
  • Recipharm Ab
  • Piramal Pharma Solutions
  • Cordenpharma International
  • Cambrex Corporation
  • Wuxi Apptec

Segments Covered in the Report:

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Product

  • API
    • By Synthetic
      • Solid
      • Liquid
    • By Type
      • Traditional Active Pharmaceutical Ingredient (Traditional API)
      • Highly Potent Active Pharmaceutical Ingredient (HP-API)
      • Antibody Drug Conjugate (ADC)
      • Others
    • By Drug
      • Innovative
      • Generics
    • By Manufacturing
      • Continuous manufacturing
      • Batch manufacturing
    • Biotech

By Drug Product

  • Oral Solid Dose
  • Semi-solid dose
  • Liquid Dose
  • Others

By Dosage Form

  • Solid
    • Tablets
    • Capsules
    • Powder
  • Semi-Solid
    • Cream
    • Paste
    • Gel
  • Liquid Dose Formulation
    • Injectables
    • Sterile Vials
    • Single Use/Single Dose
    • Multi-Use
    • Ampules
    • Prefilled Syringes
    • Suspension
    • Emulsion
  • Gas Dose Formulation
    • Inhaler
    • Aerosols

By Indication

  • Cancer
  • Cardiovascular Disease
  • Diabetes
  • Pain
  • Respiratory disease
  • Other Disease

By End-User

  • Big Pharmaceutical Companies
  • Small & Medium-Sized Pharmaceutical Companies
  • Generic Pharmaceutical Companies
  • Other End Users

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

What is the pharmaceutical CDMO market size?
The global pharmaceutical CDMO market size is expected to increase USD 172.02 billion by 2032 from USD 94.17 billion in 2022.
What will be the CAGR of global pharmaceutical CDMO market?
The global pharmaceutical CDMO market will register growth rate of 6.21% between 2023 and 2032.
Who are the prominent players operating in the pharmaceutical CDMO market?
The major players operating in the pharmaceutical CDMO market are Bushu Pharmaceuticals Ltd., Nipro Corporation, Thermo Fisher Scientific Inc., Samsung Biologics, Laboratory Corporation of America Holdings, Siegfried Holding Ag, Catalent, Inc, Lonza Group AG, Recipharm Ab, Piramal Pharma Solutions, Cordenpharma International, Cambrex Corporation, Wuxi Apptec, and Others.
Which are the driving factors of the pharmaceutical CDMO market?
The driving factors of the pharmaceutical CDMO market are the increase in the investment in research and development programs from the pharmaceutical industry, increase in chronic disease treatment, and increase in the geriatric population.

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample